Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Active Controlled, Multi-Center, Non- Inferiority Study of One-injection of Hymovis ONE (32 mg/4ml) Against Currently Approved 1-injection Regimen of Monovisc in Symptomatic Relief of Osteoarthritis of the Knee

NCT06528600 is registered in ClinicalTrials.gov with Fidia Farmaceutici s.p.a. as lead sponsor.

NCT NCT06528600
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06528600 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Active Controlled, Multi-Center, Non- Inferiority Study of One-injection of Hymovis ONE (32 mg/4ml) Against Currently Approved 1-injection Regimen of Monovisc in Symptomatic Relief of Osteoarthritis of the Knee
Lead sponsor
Fidia Farmaceutici s.p.a.
Phase
Not applicable
Overall status
Completed
Start date
September 16, 2020
Completion date
June 15, 2024
Enrollment
350 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis, knee